title: Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Young
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Squires
authors.forename: Karen
authors.initials: K
authors.lastname: Tashima
authors.forename: Keith
authors.initials: K
authors.lastname: Henry
authors.forename: Stefan
authors.initials: S
authors.lastname: Schneider
authors.forename: Anthony
authors.initials: A
authors.lastname: LaMarca
authors.forename: Henry H
authors.initials: HH
authors.lastname: Zhao
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Ross
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shaefer
mesh_terms: D019380:Anti-HIV Agents; D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides; D005919:Glomerular Filtration Rate; D015658:HIV Infections; D015497:HIV-1; D006801:Humans; D019259:Lamivudine; D009842:Oligopeptides; D011725:Pyridines; D019438:Ritonavir; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides; D019259:Lamivudine; D009842:Oligopeptides; D011725:Pyridines; D019438:Ritonavir; D000099227:Abacavir
keywords: Antiretroviral therapy,; GFR,; Kidney function; Renal impairment,